$INSM News
Last published 2w ago
- 2w agoINSMInsmed Third-Quarter 2026 Financial Results - INSMED INCEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to the INSMED third quarter 2026 financial results conference call. After today's prepared remarks, we will host a question and answer session. If you would like to a
- 2w agoINSMINSMED Inc - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoINSMInsmed Reports Third-Quarter 2026 Financial Results and Provides Business UpdatePR Newswire—Total Company Revenues of $524.4 Million for the Third Quarter of 2026——BRINSUPRI® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Quarter of
- 3w agoINSMCCCCInsmed Appoints Two New Directors to Its BoardPR Newswire—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors—BRIDGEWATER, N.J., Oct. 20, 2026
- 4w agoINSMInsmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026PR Newswire—Insmed's Largest Parallel-Running Clinical Effort to Date With Four Pivotal Phase 3 Studies Advancing Across Four Progressive Pulmonary Diseases: PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF——One of the Broadest
- 1mo agoINSMInsmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026PR Newswire—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated
- 1mo agoINSMInsmed Announces CFO TransitionPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 1mo agoINSMFDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027PR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 1mo agoINSMInsmed Expands Community Impact During Fifth Annual Global Day of GoodPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 1mo agoINSMMorgan Stanley 24th Annual Global Healthcare Conference - INSMED INCEarnings Call TranscriptsHello, everyone. I'm Max Skor, a biotech analyst with Morgan Stanley. And before we get started, for important disclosures, please see the Morgan Stanley Research Disclosure website, www.morganstanley.com forward slash r
- 2mo agoINSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 2mo agoINSMInsmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026PR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 2mo agoINSMInsmed to Present at September 2026 Investor ConferencesPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 2mo agoINSMBRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung DiseasePR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 3mo agoINSMInsmed Second Quarter 2026 Financial Results - INSMED INCEarnings Call TranscriptsThank you for standing by and welcome to the INSMED second quarter 2026 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a
- 3mo agoINSMInsmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026PR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 4mo agoINSM12-Month Results from Ongoing Open-Label Extension Study of TPIP in PAH Patients - INSMED INCEarnings Call TranscriptsThank you for standing by and welcome to the INSMED 12-month results from ongoing open label extension study of TPIP in PAH patients conference call. All lines have been placed on mute to prevent any background noise. Af
- 4mo agoINSMInsmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial HypertensionPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 4mo agoPVLASVRASLNOSBBP+2Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of DirectorsGlobeNewswireBrings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease
- 4mo agoINSMApproval of Arikayce Kit, Nda #207356 (Labeling)FDA Approved DrugsApproval Date: 06/25/2026; Drug Name: Arikayce Kit, Nda #207356; Active Ingredients: AMIKACIN SULFATE; Company: Insmed Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 207356
- 4mo agoINSMInsmed Appoints Samuele Butera as Senior Vice President, General Manager, Global RespiratoryPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 5mo agoSPCX.NDXCRWVVRSK+15Jim Cramer says SpaceX’s blockbuster IPO could have major implications for the week aheadCNBCCNBC’s Jim Cramer said the successful debut of SpaceX could pave the way for more AI-related offerings and help create a more constructive backdrop for stocks.
- 5mo agoALABCHTRCRWVCTSH+7Nasdaq-100 Index® June 2026 Quarterly ChangesGlobeNewswireNEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the June 2026 quarterly rebalance of the Nasdaq-100 Index® (NDX®), which will become effective prior to market
- 5mo agoINSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 5mo agoINSMInsmed to Present at the 2026 Goldman Sachs Annual Global Healthcare ConferencePR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 6mo agoINSMInsmed First Quarter 2026 Financial Results - INSMED INCEarnings Call TranscriptsThank you for standing by. My name is Danica and I will be your conference operator today. At this time, I would like to welcome everyone to the INSMED first quarter 2026 financial results conference call. All lines have
- 6mo agoINSMInsmed Reports First-Quarter 2026 Financial Results and Provides Business UpdatePR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 6mo agoINSMInsmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of BronchiectasisPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 6mo agoINSMInsmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026PR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 6mo agoINSMInsmed to Present at May 2026 Investor ConferencesPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 6mo agoINSMInsmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026PR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 7mo agoINSMInsmed Provides Clinical Update on Phase 2b CEDAR StudyPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 7mo agoINSMInsmed Phase 3b ENCORE Study of ARIKAYCE In Patients With Newly Diagnosed MAC Lung Infection Not Yet Treated With Antibiotics - INSMED INCEarnings Call TranscriptsThank you for standing by, and welcome to the INSMED Phase 3B Encore Study of Era Case in Patients with Newly Diagnosed MAC Lung Infection Not Yet Treated with Antibiotics Conference Call. All lines have been placed on m
- 7mo agoINSMInsmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung DiseasePR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 8mo agoINSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 8mo agoINSMInsmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business UpdatePR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 9mo agoINSMInsmed To Present at March 2026 Investor ConferencesPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 9mo agoINSMInsmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026PR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 9mo agoINSMInsmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 CongressPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 10mo agoINSMInsmed Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferencePR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 10mo agoINSMInsmed To Present at the 44th Annual J.P. Morgan Healthcare ConferencePR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 11mo agoINSMInsmed Provides Clinical and Business UpdatePR NewswireInsmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 11mo agoALNYBIIBCDWFER+9Annual Changes to the Nasdaq-100 Index®GlobeNewswireNEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on
- 11mo agoINSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 11mo agoBMYINSMMRKPFE+1Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter NowGlobeNewswireAUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more
- 11mo agoINSMEuropean Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European UnionPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver therapies to transform the lives of patients...
- 11mo agoINSMEuropean Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European UnionPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 1y agoINSMInsmed Strengthens Communities Worldwide During Fourth Annual Global Day of GoodPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 1y agoINSMInsmed To Present at November and December 2025 Investor ConferencesPR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
- 1y agoINSMInsmed Reports Third-Quarter 2025 Financial Results and Provides Business UpdatePR NewswireInsmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...